^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoKey™ SL 525 Plus Assay

    Company:
    Luye Group
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    9ms
    MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial (IASLC-WCLC 2023)
    Here we report the results of an extensive biomarker analysis conducted among participating to the SQUINT trial, a prospective, randomized phase II trial comparing the combination of nivolumab and ipilimumab (NI) versus nivolumab plus platinum-based chemotherapy (N-CT) in untreated advanced LSCC. Paraffin-embedded tumor samples were obtained from all patients participating to the SQUINT trial. Mutations in MAPK1/MAPK3 signaling genes predict longer PFS and OS in advanced LSCC treated with immunotherapy.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • MAPK1 (Mitogen-activated protein kinase 1) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    |
    STK11 mutation • KEAP1 mutation
    |
    OncoKey™ SL 525 Plus Assay
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    over1year
    MOLECULAR PREDICTORS OF IMMUNOTHERAPY EFFICACY IN LUNG SQUAMOUS-CELL CARCINOMA (LSCC): RESULTS FROM THE RANDOMIZED PROSPECTIVE SQUINT TRIAL (AIOM 2022)
    The randomized, prospective, phase II SQUINT trial was designed to assesses the efficacy of nivolumab plus investigator-choice platinum-based chemotherapy (N-CT) versus the combination of nivolumab and ipilimumab (NI) in patients with advanced/metastatic LSCC. Results of the SQUINT trial showed no difference between NI and N-CT for any clinical end-point. Correlative biomarker analyses will be presented at the Meeting.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 underexpression • PD-L1 negative
    |
    OncoKey™ SL 525 Plus Assay
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    over1year
    Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial (ESMO 2022)
    The SQUINT trial was a randomized, prospective, phase II trial which assesses the efficacy of nivolumab plus investigator-choice platinum-based chemotherapy (N-CT) versus the combination of nivolumab and ipilimumab (NI) in patients with advanced/metastatic LSCC. Conclusions Results of the SQUINT trial showed no difference between NI and N-CT for any clinical end-point. Correlative biomarker analyses will be presented at the meeting.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 underexpression • PD-L1 negative
    |
    OncoKey™ SL 525 Plus Assay
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2years
    Vela Diagnostics launches focused (60 genes) and comprehensive (525 genes) NGS-based pan-cancer panels (VelaDx Press Release)
    "Vela Diagnostics announced today the launch of its new OncoKey® SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run."
    Launch
    |
    OncoKey™ SL 525 Plus Assay • OncoKey™ SL 60 Plus Assay